# Enzalutamide

## Xtandi 40mg (tablet)

| TAH Drug Code      | [OXTA40](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OXTA40)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment for: (1) Metastatic castration-sensitive prostate cancer (mCSPC) in combination with androgen deprivation therapy. (2) High-risk non-metastatic castration-resistant prostate cancer. (3) Metastatic castration-resistant prostate cancer with asymptomatic or mild symptoms not requiring chemotherapy after failure of androgen deprivation therapy. (4) Metastatic castration-resistant prostate cancer who have received docetaxel treatment.                                                                                                                                                                                                                  |
| Dosing             | Recommended dose: Enzalutamide 160 mg daily (4 tablets of 40 mg or 2 tablets of 80 mg). Continue LHRH analog for non-surgical castration. In case of Grade ?3 toxicity， pause treatment until Grade ?2 is reached， then resume at full or reduced dose (120 mg or 80 mg). Avoid potent CYP2C8 inhibitors; if needed， reduce enzalutamide dose to 80 mg daily.                                                                                                                                                                                                                                                                                                             |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Hypersensitivity to Xtandi， enzalutamide or any component of the formulation. Pregnant women or women who may be pregnant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Adverse Effects    | Common: Hypertension (8-14.2%)， Peripheral edema (11.5-15.4%)， Flushing (13-69%)， Weight decreased (5.9-12.4%)， Constipation (9.1-23.2%)， Decrease in appetite (4.9-19%)， Diarrhea (11.5-21.8%)， Taste sense altered (7.6%)， Arthralgia (20.5-21.4%)， Backache (19.1-28.6%)， Musculoskeletal pain (6.3-50%)， Asthenia， Including fatigue (24-50.6%)， Dizziness， and vertigo (9.5-12%)， Headache (9.1-12.1%)， Dyspnea (11%)， Upper respiratory infection (10.9-16%)， Fatigue (50-54%). Serious: Hypersensitivity reaction (0.1-0.5%)， Cauda equina syndrome， Posterior reversible encephalopathy syndrome， Seizure (0.6-2.2%)， Spinal cord compression. |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/enzalutamide-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

